Abstract
The availability of recombinant human erythropoietin (rhuEPO) has dramatically improved the care of children with chronic renal failure (CRF). Its use provides the opportunity to determine the relative contribution of anemia to the morbidity of CRF. Growth retardation, one of the most significant complications of CRF in children, is the consequence of several inter-related processes, including decreased protein and energy intake, metabolic bone disease, endocrine abnormalities, and anemia. The literature on the use of rhuEPO in children and data from a United States phase III double-blind, placebo-controlled study of rhuEPO in pediatric dialysis patients are reviewed to determine the effect of rhuEPO treatment on the nutritional status and growth of children with CRF. Despite subjective increases in appetite, there were no consistent improvements in dietary intake or anthropometric measures observed during rhuEPO treatment. Children gained weight during rhuEPO treatment; however, this was not generally associated with increased weight standard deviation scores. There was an improvement in growth velocity in some children; however, improvements in height standard deviation scores were infrequently seen. On review of the available literature, correction of anemia with rhuEPO has not been shown to improve the growth of children with CRF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McGonigle RJS, Boineau FG, Beckman B, Ohene-Frempong K, Lewy JE, Shadduck RK, Fisher JW (1985) Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med 105: 449–458
Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992–1000
Potter DE, Greifer I (1978) Statural growth of children with renal disease. Kidney Int 14: 334–339
Kleinknecht C, Broyer M, Huot D, Marti-Henneberg C, Dartois AM (1983) Growth and development of nondialyzed children with chronic renal failure. Kidney Int 24 [Suppl 15]: S40-S47
Rizzoni G, Basso T, Setani M (1984) Growth in children with chronic renal failure on conservative treatment. Kidney Int 26: 52–58
Blum WF, Ranke M, Kietzmann K, Tönshoff B, Mehls O (1991) GH resistance and inhibition of IGF activity by excess IGF-binding proteins in uremia. Pediatr Nephrol 5: 539–544
Powell DR, Liu F, Baker B, Lee PD, Belsha CW, Brewer ED, Hintz RL (1993) Characterization of insulin-like growth factor binding protein-3 in chronic renal failure serum. Pediatr Res 33: 136–143
Kramer MS, Rooks Y, Washington L, Pearson HA (1980) Pre and postnatal growth and development in children with sickle cell anemia. J Pediatr 96: 857–860
Kattamis C, Touliatos N, Haidas S, Matsaniotis N (1970) Growth of children with thalassemia and effect of different transfusion regimens. Arch Dis Child 45: 502–505
Jabs K, Alexander S, McCabe D, Lerner G, Harmon W (1994) Primary results from the U. S. multicenter pediatric recombinant erythropoietin study (abstract). J Am Soc Nephrol 5: 456
Van Dop C, Jabs KL, Alexander S, Salusky IB, McCabe D (1995) Correction of anemia does not improve growth or endocrine function in children with ESRD: a report from the U. S. multicenter pediatric recombinant erythropoietin study (abstract). J Am Soc Nephrol 6: 407
Hamill PVV (ed) (1977) Growth curves for children. DHEW publication no. (PHS) 78-1650. National Center for Health Statistics, Washington, D. C.
Campos A, Garin EH (1992) Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rhuEPO). Clin Pediatr (Phila) 31: 94–99
Navarro M, Alonso A, Avilla JM (1991) Anemia of chronic renal failure: treatment with erythropoietin. Child Nephrol Urol 11: 146–151
Sinai-Trieman L, Salusky IB, Fine RN (1989) Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 114: 550–554
Warady BA, Sabath RJ, Smith CA, Alon U, Hellerstein S (1991) Recombinant human erythropoietin in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 5: 718–723
Stefanidis CJ, Koulieri A, Siapera D, Kapogiannis A, Mitsioni A, Michelis K (1992) Effect of correction of anemia with recombinant human erythropoietin on growth of children treated with CAPD. Adv Perit Dial 8: 460–463
Morris KP, Sharp J, Watson S, Coulthard MG (1993) Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child 69: 580–586
Scigalla P, Bonzel KE, Bulla M, Burghard R, Dippel J, Geisert J, Leumann E, Lilien T, Müller-Wiefel DE, Offner G, Pistor K, Zoellner K (1989) Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. In: Baldamus CA, Scigalla P, Wieczorek L, Koch KM (eds) Erythropoietin: from molecular structure to clinical application. Contrib Nephrol 76: 227
Pietrzyk JA, Smolnik T, Szymowska M, Dyras P, Lenik J (1992) Effect of recombinant human erythropoietin — rHu-EPO on the metabolism of children treated by long-term hemodialysis. Przegl Lek 49: 55–60
Jabs K, Harmon W (1990) Double-blind, placebo-controlled study of the use of Epoetin Alfa in pediatric hemodialysis patients (abstract). J Am Soc Nephrol 1: 400
Offner G, Hoyer PF, Latta K, Winkler L, Brodehl J, Scigalla P (1990) One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory of cycling peritoneal dialysis. Pediatr Nephrol 4: 498–500
Scigalla P (1991) Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. In: Gurland HJ, Moran J, Samtleben W, Scigalla P, Wieczorek L (eds) Erythropoietin in renal and nonrenal anemias. Contrib Nephrol 88: 201
Rees L, Rigden SP, Chantler C (1991) The influence of steroid therapy and recombinant human erythropoietin on the growth of children with renal disease. Pediatr Nephrol 5: 556–558
Schärer K, Klare B, Braun A, Dressel P, Gretz N (1993) Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure. Acta Paediatr 82: 953–958
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jabs, K. The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 10, 324–327 (1996). https://doi.org/10.1007/BF00866771
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00866771